PHP
RCKT icon

Parkman Healthcare Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Parkman Healthcare Partners’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-26,677
Closed -$367K – 96
2022
Q2 		$367K Buy
26,677
+1,382
+5% +$16.5K 0.14% 71
2022
Q1 		$401K Buy
+25,295
New +$437K 0.12% 77

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Parkman Healthcare Partners's RCKT Position: Q3 2022 in Review

Parkman Healthcare Partners sold out of Rocket Pharmaceuticals (RCKT) in Q3 2022, closing a stake of 26,677 shares — an estimated $367K sold.

Parkman Healthcare Partners first reported a position in RCKT in Q1 2022 and held it in 2 quarters. The position peaked at $401K in Q1 2022. 164 funds tracked by Wall St. Rank hold RCKT as of Q3 2022.

  • Parkman Healthcare Partners reported no remaining Rocket Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Parkman Healthcare Partners sold 26,677 Rocket Pharmaceuticals shares in Q3 2022, an estimated $367K.
  • Parkman Healthcare Partners first reported a position in Rocket Pharmaceuticals in Q1 2022 and held it in 2 quarters.
  • Parkman Healthcare Partners's Rocket Pharmaceuticals position peaked at $401K in Q1 2022.
  • 164 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2022.

Based on Parkman Healthcare Partners's 13F filing for Q3 2022, filed 14 Nov 2022.